-
Mashup Score: 0INV-1120 Proves Tolerable in Advanced Solid Tumors, Moves to Expansion in Combination With Pembrolizumab - 1 year(s) ago
Treatment with INV-1120 was well tolerated and demonstrated preliminary signals of stable disease as a single agent in patients with advanced solid tumors.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Disparities in clinical trial recruitment can be attributed to poorer social determinants of health in communities of color including worse…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Improving anti-CTLA4 efficacy in neuroblastoma via the induction of mismatch repair deficiency - 1 year(s) ago
Saman Maleki, PhD, Western University, London, Canada, talks on improving immunotherapy for neuroblastoma tumors, a form of childhood cancer. Neuroblastoma…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Diwakar Davar, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, describes the mechanism of action of vidutolimod. The novel CpG-A Toll-like…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Budigalimab Plus ABBV-151 Demonstrates Variable Activity Across Locally Advanced or Metastatic Solid Tumors - 1 year(s) ago
The addition of budigalimab to ABBV-151 was well tolerated and significantly enhanced responses in patients with locally advanced or metastatic solid tumors.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Microbiome modification with fecal transplant before IO to reduce primary resistance in melanoma - 1 year(s) ago
Saman Maleki, PhD, Western University, London, Canada, provides an overview of an investigation into microbiome modification with fecal microbiota transplant…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Carmen Guerra, MD, MSCE, FACP, Perlman School of Medicine at the University of Pennsylvania, discusses the need to reduce unconscious…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Delta-radiomics predicting response and overall-survival in advanced NSCLC treated with durvalumab - 1 year(s) ago
Anant Madabhushi, PhD, Emory University School of Medicine, Atlanta, GA, discusses findings on delta-radiomics predicting response and overall-survival in patient…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0The correlation between composition of the gut microbiota with anti-PD-1 efficacy in cancer patients - 1 year(s) ago
Saman Maleki, PhD, Western University, London, Canada, discusses the correlation between the composition of the gut microbiota with anti-PD-1 efficacy…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0How can racial disparities affect patient care in oncology? - 1 year(s) ago
Carmen Guerra, MD, MSCE, FACP, Perlman School of Medicine at the University of Pennsylvania, describes how racial disparities in oncology…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
INV-1120 Proves Tolerable in Advanced Solid Tumors, Moves to Expansion in Combination With Pembrolizumab @sitcancer #SITC2022 #SITC22 https://t.co/7nwda8RDiC